Document:

Exhibit 10.22

 

Laboratory Services and Confidentiality Agreement - Amendment 1*

Radius Health, Inc.

 

FIRST AMENDMENT TO LABORATORY SERVICES 
 AND CONFIDENTIALITY AGREEMENT

 

This is a First Amendment (“Amendment”) to Laboratory Services and Confidentiality Agreement dated as of the 7th day of November, 2008 (the “Effective Date”), amending the Laboratory Services and Confidentiality Agreement (“Agreement”) dated March 31st, 2004 between Charles River Laboratories, Inc. (“Laboratory”) and Radius Health, Inc. (formerly known as Nuvios, Inc.) (“Sponsor”).  All undefined terms contained herein shall have the meaning set forth in the Agreement.

 

WHEREAS, Sponsor and Laboratory wish to amend the Agreement as hereafter provided.

 

NOW, THEREFORE, for good and valuable consideration and intending to be legally bound, the parties hereby agree as follows:

 

1.                                       The Services may be performed by Laboratory or any of its affiliates at any of the facilities listed on Exhibit A attached hereto and made a part hereof.

 

2.                                       Notices from Sponsor to Laboratory shall be addressed to the applicable facility at the address listed on Exhibit A, with copies as indicated on Exhibit A.

 

3.                                       Notices from Laboratory to Sponsor shall be addressed to:

 

“Radius Health, Inc.
 300 Technology Square
 Cambridge, MA 02139
 Attn: Chief Financial Officer”

 

4.                                       The Agreement between Laboratory and Sponsor is hereby amended to extend the term until March 31st, 2014.

 

5.                                       All Services shall be performed in accordance with the Supporting Documents applicable to the Services and shall be performed in accordance with the applicable laws and regulations of said jurisdiction.

 

6.                                       Section 11.2 of the Agreement will be replaced in its entirety with the following:

 

“Laboratory’s liability under this Agreement, regardless of the form of action, shall not exceed [*] provided under the Letter of Payment Authorization under which such liability arises.

 

7.                                       Section 19.3 of the Agreement will be replaced in its entirety with the following:

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

1

 

“This Agreement, and the rights and obligations hereunder, may not be assigned or transferred by Laboratory without the prior written consent of Sponsor. However, Laboratory may, without the consent of Sponsor, transfer or assign this Agreement, in whole or in part to an affiliate, or in connection with a merger, consolidation, or a sale or transfer of all or substantially all of the assets to which this Agreement relates, provided that Laboratory notifies Sponsor [*] ([*]) days prior to such merger, consolidation, sale or transfer, and provided that all obligations of Laboratory are assumed by the assignee. Sponsor may assign this Agreement in whole or in part without consent of Laboratory. No assignment will relieve either party of the performance of any accrued obligation that such party may then have under this Agreement.”

 

8.                                       All other terms and conditions of the Agreement, as amended and modified, are hereby ratified, confirmed and approved.

 

IN WITNESS WHEREOF, duly authorized representatives of the parties have signed this Amendment as of the Effective Date.

 

	
Charles   River Laboratories, Inc.
    	
 
    	
Sponsor
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Chris Perkin
    	
 
    	
By:
    	
/s/ B.N.   Harvey
    
	
 
    	
duly   authorized
    	
 
    	
 
    	
duly   authorized
    
	
 
    	
 
    	
 
    
	
For   Print Name: Chris Perkin, D.A.B.T.
    	
 
    	
Print   Name: B.N. Harvey
    
	
Title:
    	
Corporate   Senior Vice President & President,
    	
 
    	
Title: CFO
    
	
 
    	
Canadian &   Chinese Preclinical Services
    	
 
    	
 
    
	
Date:
    	
November 12,   2008
    	
 
    	
Date: 11/12/08
    
						

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

2

 

Exhibit A

 

Work may be conducted at any of the following Charles River Laboratories locations:

 

	
905   Sheehy Drive, Building A

Horsham,   PA 19044

Tel:   (215)-443-8710

Fax:   (215) 443-8587
    	
 
    	
640   N. Elizabeth Street

Spencerville,   OH 45887

Tel:   (419) 647-4196

Fax:   (419) 647-6560
    
	
 
    	
 
    	
 
    
	
100   East Boone Street

Redfield,   AR 72132

Tel:   (501) 397-2540

Fax:   (501) 397-2002
    	
 
    	
15   Worman’s Mill Court, Suite I

Frederick,   MD 21701

Tel:   (301) 663-1644

Fax:   (301) 663-8994
    
	
 
    	
 
    	
 
    
	
358   Technology Drive

Malvern,   PA 19355

Tel:   (610) 640-4550

Fax:   (610) 889-9029
    	
 
    	
587   Dunn Circle

Sparks,   NV 89431

Tel:   (775) 331-2201

Fax:   (775) 331-2289
    
	
 
    	
 
    	
 
    
	
6996   Longley Lane

Reno,   NV 89511

Tel:   (775) 682-2000

Fax:   (775) 682-2100
    	
 
    	
22022   Transcanadienne

Senneville,   Quebec

H9X   3R3, Canada

Tel:   (514) 630-8200

Fax:   (514) 630-8230
    
	
 
    	
 
    	
 
    
	
Elphinstone   Research Center

Tranent   , Edinburgh EH33 2NE

Scotland   UK

Tel:   011 +44 1875 614 545

Fax:   011 +44 1875 614 555
    	
 
    	
Carrentrila

Ballina, Co.   Mayo

Ireland

Tel:   011 +353 96 20800

Fax:   011 +353 96 22517
    
	
 
    	
 
    	
 
    
	
251   Ballardvale Street

Wilmington,   MA 01887

Tel:   (978) 658-6000

Fax:   (978) 658-7132
    	
 
    	
334   South Street

Shrewsbury,   MA 01545

Tel:   (508) 925-6900
    
	
 
    	
 
    	
 
    
	
3615   Pacific Avenue

Tacoma,   WA 98418

Tel:   (253) 593-5304

Fax:   (253) 593-5181
    	
 
    	
1023   Wapoo Road

Charleston,   SC 29407

Tel:   (843) 766-7575

Fax:   (843) 766-7576
    
	
 
    	
 
    	
 
    
	
4025   Stirrup Creek Drive, Suite 150

Durham,   NC 27703

Tel:   (919) 206-7007

Fax:   (919) 206-7001
    	
 
    	
2255   W. Harrison

Chicago, IL   60612

Tel:   (312) 666-1555

Fax:   (312) 666-1764
    
	
 
    	
 
    	
 
    
	
200   NE Missouri Road – Suite 104

Lee’s   Summit, MO 64086

Tel:   (508) 925-6540

Fax:   (816) 525-0076
    	
 
    	
 
    

 

A COPY OF ALL NOTICES SHALL BE SENT TO:

 

	
Charles   River Laboratories, Inc.

251   Ballardvale Street

Wilmington,   MA 01887

Attn:   General Counsel

Tel   (978) 658-6000

Fax: (978) 658-988-5665
    	
 
    	
Charles   River Laboratories, Inc.

251   Ballardvale Street

Wilmington   MA 01887

Attn:                    Heidi Oskar,   Senior Contracts Administrator

Tel   (978) 658-6000

Fax: (978) 988-5827
    

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

3Exhibit 10.24

 

 

Letter of Payment Authorization*

 

February 1st, 2011

 

Gary Hattersley, Ph.D.
 Vice President, Biology
  RADIUS HEALTH, INC.
  5th Floor
 300 Technology Square
 Cambridge, MA 02139
 United States
 ghattersleyaradiuspharm.com

 

Dear Gary,

 

We thank you for your interest in Charles River and hope the attached proposal meets with your approval.  For your convenience, we have provided the following summary of the titles and prices of the studies and/or study components under discussion.  If you would like us to proceed with animal orders resource allocation, sign and date the authorization line below.  (If all studies and/or components are not being authorized at this time, please initial the studies and components you wish to authorize and sign and date the authorization line below.  If all studies are being authorized at this time, merely sign and date the authorization line below, leaving the studies and component boxes empty).  These prices are valid for [*] days, but may be modified by mutual agreement if changes to the scope of work are made.

 

	
Authorization
   Initials
    	
 
    	
Study Number and Title
    	
 
    	
Price
    	
 
    
	
 
    	
 
    	
670646
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
A   [*]-Month Osteoporosis Intervention Study In The Ovariectomized [*]
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
(based   on Draft Protocol version 2)
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Study Price: 
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Biomechanics: 
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Biomarkers: 
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Bone Densitometry: (DXA + pQCT) 
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Histomorphometry:  
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Total Price: 
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Price with [*]% pre-discount: 
    	
 
    	
$
    	
[*] US
    	
 
    
	
 
    	
 
    	
Total price with [*]% MPM discount: 
    	
 
    	
$
    	
[*] US
    	
 
    

 

In order to minimize the impact of study delays and cancellations for all sponsors, Charles River allocates resources at the time a signed Letter of Payment Authorization is received.  Please note that scheduling is not considered confirmed until a signed copy of this document is received.  By providing authorization via signature below, you will allow us to confirm a schedule for each authorized study.  Your signature further constitutes acceptance of the price and payment schedule.

 

Payment Schedule for Study # 670646

 

The payment schedule of this study is as follows:

 

· [*]%    Due at animal arrival

· [*]%    Equal Monthly Installment

· [*]%    Due upon Submission of Draft Report

· [*]%    Due upon Submission of Final Report

 

Based upon the current scope of work, we would propose the animal arrival in [*].  Prior to receipt of this signed Letter of Payment Authorization this initiation date may be lost to another study vying for the same resources.

 

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission.

 

1

 

We understand that occasionally you may request to delay or to cancel a study due to unforeseen circumstances.  Charles River will make every commercially reasonable effort to accommodate requested schedule changes.

 

Charles River shall perform these services in accordance with the services agreement (the “Agreement”) executed between Charles River and RADIUS HEALTH, INC.  Once fully executed, this Letter of Payment Authorization shall be incorporated into and made part of the Agreement.

 

STUDY MATERIAL STORAGE/ARCHIVES.  After dispatch of the draft report, all raw data, samples/specimens (except for those sent to Sponsor or Sponsor designated laboratory and resultant data which are the responsibility of Sponsor) and documents generated at Charles River during this study, together with the original copy of the protocol (including amendments) and the draft report, will be retained in the secure storage area of Charles River for [*] ([*]) year at no charge.  After this [*] ([*]) year period, Sponsor will be contacted prior to the end of the year to authorize continued storage or return to Sponsor, at additional cost.  At finalisation, the final report and any stored materials will be transferred to the scientific archives of Charles River.  Subsequently, storage details will be documented in the raw data.

 

Any additional storage, archiving or retention will require an Extended Archiving Agreement.

 

REPEAT OF SAMPLE ANALYSIS.  If applicable for studies involving bioanalytical sample analysis, the parties agree that as of commencement of work, in some instances, repeat of sample analysis will be required.  If this arises, Charles River must notify the Sponsor as soon as possible and determine, between the parties, if these repeats are required by Sponsor.  Consequently, the price per sample analysis/occasion will apply to any additional repeats requested by the Sponsor, as well as any samples above the analytical range, which require dilution.  However, in the event that additional sample analysis/occasions are required, Charles River shall submit a written estimate to the Sponsor for the Sponsor’s written approval, and the Sponsor shall respond to Charles River within [*] ([*]) business days, or within the specified time period sanctioned by the Sponsor for receipt of such estimates.  Once authorization is received, Charles River will endeavor, when possible, to proceed with current batches of sample analysis.  Both parties acknowledge that Charles River will be reimbursed for any amount which relates to the repeats if the difference between the original result of the sample analysis and the repeat result of the sample analysis, is within a [*]% range.

 

SHIPMENT OF TEST ARTICLES.  Sponsor and Charles River agree that all costs associated with shipping test article to Charles River shall be the responsibility of the Sponsor.  Charles River shall not be responsible for any direct or indirect damages sustained by the Sponsor resulting from any loss, destruction or damage to the test article(s).

 

In the event of a conflict between the terms set forth in this Letter of Payment Authorization and the Agreement, the terms of the Master Service Agreement shall control, unless specifically agreed upon to the contrary in this letter.

 

Please sign and return this document via facsimile or email (contact information below).  Should you have any questions or require any additional information, please do not hesitate to call me. We look forward to being of service.

 

Best regards,

 

	
 
    	
 
    	
/s/   B. N. Harvey
    
	
 
    	
 
    	
Authorized   Sponsor Representative
    
	
/s/   Stephane Besner
    	
 
    	
 
    
	
Stephane   Besner, B.Sc., M.B.A.
    	
 
    	
 
    
	
Client   Manager, Sales & Marketing
    	
 
    	
 
    
	
Charles   River Laboratoires
    	
 
    	
B.   N. Harvey, CFO
    
	
Preclinical   Services Montreal Inc.
    	
 
    	
Date
    	
Feb   3, 2011
    

 

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission.

 

2

 

	
22022   Transcanadienne
    	
 
    	
Print   (Name and Title)
    
	
Senneville, Québec, Canada H9X 3R3
    	
 
    	
 
    
	
Tel:   (514) [*]
    	
 
    	
 
    
	
Fax:   (514) [*]
    	
 
    	
 
    
	
e-mail:[*]
    	
 
    	
Date
    
	
Web   site: www.criver.com
    	
 
    	
 
    

 

If a PO is required, please submit PO with Letter of Payment Authorization or fax to 514-630-8230.

 

	
Charles   River Laboratories
   Preclinical Services Montréal Inc.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/   Michele Marcoux
    	
 
    	
 
    
	
Michele   Marcoux, CMA
   Director, Finance
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Feb   7, 2011
    	
 
    	
 
    
	
Date
    	
 
    	
 
    

 

A counter signed version of this document will be returned to you for your records.

 

c.c. M. Marcoux, S. Pryce, D. Tremblay, S Y. Smith, Main File

 

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission.

 

3

 

Date Created: March 12, 2010
 Sponsor: Radius Health, Inc.

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]